Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

[1]  N. Bressler,et al.  Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. , 2015, Ophthalmology.

[2]  P. Kaiser,et al.  Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.

[3]  Jennifer K. Sun,et al.  Complications of Intravitreal Injections in Patients with Diabetes , 2014, Seminars in ophthalmology.

[4]  P. Mitchell,et al.  Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. , 2014, Ophthalmology.

[5]  A. Harris,et al.  Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant , 2014, Expert opinion on pharmacotherapy.

[6]  R. Simó,et al.  Ocular Anti-VEGF Therapy for Diabetic Retinopathy: The Role of VEGF in the Pathogenesis of Diabetic Retinopathy , 2014, Diabetes Care.

[7]  J. Sorof,et al.  Anti-vascular endothelial growth factor therapy for diabetic macular edema , 2013, Therapeutic advances in endocrinology and metabolism.

[8]  A. Messias,et al.  A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. , 2013, American journal of ophthalmology.

[9]  L. Aiello,et al.  Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. , 2012, Ophthalmology.

[10]  Ursula Schmidt-Erfurth,et al.  One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. , 2012, Ophthalmology.

[11]  T. Peto,et al.  A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. , 2012, Archives of ophthalmology.

[12]  Quan Dong Nguyen,et al.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. , 2012, Ophthalmology.

[13]  B. Klein,et al.  Global Prevalence and Major Risk Factors of Diabetic Retinopathy , 2012, Diabetes Care.

[14]  G. Yancopoulos,et al.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab , 2012, Angiogenesis.

[15]  Thomas W. Gardner,et al.  The restore study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema , 2011 .

[16]  Ursula Schmidt-Erfurth,et al.  The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. , 2011, Ophthalmology.

[17]  Jennifer K. Sun,et al.  Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. , 2011, Ophthalmology.

[18]  Lloyd Paul Aiello,et al.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema , 2010, Ophthalmology.

[19]  T. Peto,et al.  A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. , 2010, Ophthalmology.

[20]  Lynn A. Karoly,et al.  Health Insurance Portability and Accountability Act of 1996 (HIPAA) Administrative Simplification , 2010, Practice Management Consultant.

[21]  Lloyd Paul Aiello,et al.  Angiogenic pathways in diabetic retinopathy. , 2005, The New England journal of medicine.

[22]  B. Zinman,et al.  Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. , 2003, Diabetes care.

[23]  J. Rakic,et al.  Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.

[24]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Resnikoff,et al.  Visual impairment and blindness in Europe and their prevention , 2002, The British journal of ophthalmology.

[26]  J. Marshall,et al.  The pathogenesis of edema in diabetic maculopathy. , 1999, Seminars in ophthalmology.

[27]  A. Act.  Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema , 2015 .

[28]  Gbd Vleg.  Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. , 2014 .